XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2

License Agreements (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
License Agreements
Research and development expense		$ 3,384,000	$ 4,683,000	$ 11,589,000	$ 12,584,000
Rosetta Genomics Ltd.
License Agreements
Research and development expense						$ 1,600,000
Up front and milestone payments	$ 1,600,000
Aggregate payments to be made for each licensed product upon achievement of certain development and regulatory milestones		3,000,000		3,000,000
Marina Biotech Inc.
License Agreements
Aggregate payments to be made for each licensed product upon achievement of certain development and regulatory milestones		6,000,000		6,000,000
Cumulative up-front and milestone payments		2,100,000		2,100,000
Additional payments to be made for each licensed product upon achievement of certain development and regulatory milestones for a specified number of additional indications		4,000,000		4,000,000
Maximum cap on all milestone payments per product		10,000,000		10,000,000
Aggregate of all remaining development and regulatory milestone payments upon additional indications				4,000,000.0
Yale University
License Agreements
Maximum cap on all milestone payments per product		$ 600,000		$ 600,000

X

- Definition

Represents the additional payments to be made for each licensed product upon achievement of certain development and regulatory milestones for a specified number of additional indications.

+ References

No definition available.

+ Details

Name:	mirn_LicenseAgreementAdditionalMilestonePaymentsToBeMadePerLicensedProductUponAchievementOfCertainRegulatoryMilestonesForSpecifiedNumberOfAdditionalIndications
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the maximum cap on all milestone payments per product.

+ References

No definition available.

+ Details

Name:	mirn_LicenseAgreementMaximumMilestonePaymentsPerProduct
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents, in aggregate, the payments to be made upon achievement of certain development and regulatory milestones for each licensed product.

+ References

No definition available.

+ Details

Name:	mirn_LicenseAgreementMilestonePaymentsToBeMadePerLicensedProductUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents, in aggregate, the payments to be made upon additional indications.

+ References

No definition available.

+ Details

Name:	mirn_LicenseAgreementMilestonePaymentsToBeMadePerLicensedProductUponAdditionalIndications
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of up-front and milestone payments made during the period.

+ References

No definition available.

+ Details

Name:	mirn_UpFrontAndMilestonePayments
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of cumulative up-front and milestone payments made as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	mirn_UpFrontAndMilestonePaymentsCumulative
Namespace Prefix:	mirn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirn_RosettaGenomicsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirn_MarinaBiotechLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirn_YaleUniversityLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: